A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients with Advanced Breast Cancer
Study Status
Open to Enrollment
Study Description
The purpose of this study is to compare the incidence (a measure of the risk of developing a condition) and severity of neuropathy (numbness, tingling, pain or weakness in the hands and feet) for two treatment groups (eribulin versus ixabepilone) in patients with advanced breast cancer.
Disease Status and/or Stage
Advanced Breast Cancer and Neuropathy
Sponsor
Eisai
Key Eligibility
- Women age 18 and older
- Confirmed locally recurrent or metastatic breast cancer
- Have received prior taxane therapy and at least one prior cytotoxic chemotherapy regimen for advanced breast cancer
- Other eligibility criteria will be discussed with you when you contact the study team
Principal Investigator
Contact
- Marta Cobham, RN
- 212-821-0780
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Erica Bersin
Tel: (646) 962-8232
[email protected]
